Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors

Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors

Summary: This phase 1b/2 clinical trial (NCT04775680) evaluated the safety, efficacy, pharmacokinetics and pharmacodynamics of ADG106, a ligand-blocking agonistic antibody targeting CD137 (4-1BB), combined with toripalimab in patients with advanced malignancies. ADG106 0.75–3 mg/kg plus toripalimab...

Full description

Saved in:
Bibliographic Details
Main Authors: Shaoyan Lin, Yuxiang Ma, Yongsheng Wang, Yunpeng Yang, Jinhui Xue, Yan Huang, Yuanyuan Zhao, Wenfeng Fang, Shaodong Hong, Yang Zhang, Qianwen Liu, Guizhong Liu, Xiaohong She, Jiping Zha, Songmao Zheng, Yan Li, Peter Luo, Li Zhang, Hongyun Zhao
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:iScience
Subjects:
Oncology
Clinical medicine
Therapeutics
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004225007588
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589004225007588

Similar Items